FOLH1 and prostate carcinoma: Hohberg et al. demonstrate that using 68Ga-PSMA-11, there was a higher lesion detection rate at a later imaging time point (3 h postinjection vs. 1 h postinjection) when imaging patients with recurrent prostate cancer with low PSA levels [19].